Ovoca Gold PLC (GB:TLM)
LSE:TLM
Top Page
Ovoca Gold
(LSE:TLM)
Select Model
Select Model
Rating:46Neutral
Price Target:
7.00 p
▲(508.70% Upside)
Action:ReiteratedDate:01/30/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, negative free cash flow, and equity erosion), partially offset by a debt-free balance sheet. Technicals are strong but appear extremely overbought, and valuation is limited by negative earnings and no provided dividend yield.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet removes fixed interest obligations and lowers insolvency risk, giving management structural flexibility to fund exploration or development via equity, partnerships, or phased spending. This durable strength improves resilience across 2–6 months of exploration cycles.
Negative Factors
Pre-revenue business profile
No recorded revenue means the business lacks commercial cash generation and depends on successful exploration, asset sales, or financings to create value. This structural absence of operating revenue increases execution and financing risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet removes fixed interest obligations and lowers insolvency risk, giving management structural flexibility to fund exploration or development via equity, partnerships, or phased spending. This durable strength improves resilience across 2–6 months of exploration cycles.
Read all positive factors
Ovoca Gold (TLM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£4.81M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding64,174,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio5.37
Price to Book (P/B)194.45
Price to Sales (P/S)0.00
P/FCF Ratio-352.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ovoca Gold Business Overview & Revenue Model
Company Description
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopaus...
Ovoca Gold Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
22
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Ovoca Gold Peers Comparison
UnderperformOutperform
Sector (51)
GB:TLM
Ovoca Gold
7.50
6.25
500.00%
GB:CRTX
Amur Minerals
11.00
1.50
15.79%
GB:ROQ
Roquefort Investments PLC
8.50
-8.00
-48.48%
Ovoca Gold Corporate Events
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Talisman Metals debut on AIM fuels Moroccan copper drive
Positive
Jan 28, 2026
The company has completed the reverse takeover of Tadeen International, secured AIM readmission with 64.2 million shares outstanding, and raised £1.155 million to increase total cash to about £2.255 million, supporting phased drilling pl...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingShareholder MeetingsStock Split
Ovoca Bio Shareholders Back Talisman Metals Transition and AIM Re-Admission
Positive
Jan 27, 2026
Ovoca Bio plc, soon to be renamed Talisman Metals PLC, confirmed that shareholders have approved all resolutions at both a General Meeting and an Annual General Meeting held on 27 January 2026, enabling the completion of its acquisition of Tadeen ...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingShareholder MeetingsStock Split
Ovoca Bio to Rebrand as Talisman Metals After Reverse Takeover of Moroccan Copper Explorer
Positive
Dec 31, 2025
Ovoca Bio has agreed a share-based deal to acquire up to 100% of Tadeen International Limited, a UK company whose Moroccan subsidiary holds copper-focused mineral exploration licences, marking a reverse takeover that will convert Ovoca from an AIM...
Regulatory Filings and ComplianceShareholder Meetings
Ovoca Bio Sets Date and Details for 2025 Annual General Meeting in Dublin
Neutral
Dec 31, 2025
Ovoca Bio has published and begun posting to shareholders the notice of its 2025 Annual General Meeting, which sets out the resolutions to be put to investors and is also available on the company’s website. The AGM is scheduled to take place...
Business Operations and StrategyM&A Transactions
Ovoca Bio Appoints New Broker Amid Acquisition Plans
Positive
Nov 13, 2025
Ovoca Bio PLC, a company in the biotechnology sector, has announced a change in its brokerage arrangement. The company has appointed CMC Markets UK Plc, trading as CMC CapX, as its new broker, while Beaumont Cornish Limited will continue as its No...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.